Lyme Borreliosis and Early Cutaneous Diagnostic
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT02414789
- Record updated
- 13 July 2026
- Original description
Test and evaluate a new diagnostic method (SRM-MS/MS: Selected Reaction Monitoring- Mass spectrometry) for Lyme Borreliosis on human skin biopsies. Patients included are those with the early skin manifestation (erythema migrans).Read full original descriptionShow less
Test and evaluate a new diagnostic method (SRM-MS/MS: Selected Reaction Monitoring- Mass spectrometry) for Lyme Borreliosis on human skin biopsies. Patients included are those with the early skin manifestation (erythema migrans).
This new proteomic method will be compared to the two existing method: culture of Borrelia and PCR detection of Borrelia (DNA detection of the bacteria).
Inclusion: Erythema migrant as criteria EUCALB or atypical form associated to tick's sting; Patient having signed a consent; Patient affiliated to a social security scheme.
Exclusion: Prior treatment with antibiotics; Bleeding disorders; Erythema migrans on the face; Anticoagulant treatment; Inability to give clear information (subject in an emergency situation, understanding of the topic difficulty, ...).